News for Glaukos Corporation (GKOS)

Glaukos (GKOS) delivered earnings and revenue surprises of 6.98% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

GKOS announces New Drug Application submission for its Epioxa to the FDA.

Glaukos president sells $498,715 in stock

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Liberty All-Star ® Growth Fund, Inc. October 2024 Monthly Update

Baron Health Care Fund declined in the second quarter of 2024, lagging its primary benchmark, the Russell 3000 Health Care Index.

Liberty All-Star ® Growth Fund, Inc. April 2024 Monthly Update

Several approved therapies such as EYBELIS, Durysta, Alphagan-P, Rhopressa, etc. will drive the current therapeutic landscape of ocular hypertension in the...

The dynamics of the glaucoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising...

The presbyopia market is predicted to grow during the forecast period (2023–2032) owing to the development of well-designed, randomized trials to study...

The dynamics of the adult myopia market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising...